2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.
Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.
Immunotherapy is at a very exciting point in melanoma, says Daud. Specifically, there were a number of combinations presented at the 2017 ASCO Annual Meeting for the relapse/refractory population that showed responses.
Related Content: